Michael W. Hodin, PhD

Michael W. Hodin, Ph.D. is CEO of the Global Coalition on Aging, Managing Partner at High Lantern Group, and a Fellow at Oxford University’s Harris Manchester College. He is also a blogger on Medium.

From 1976-80, Mike was Legislative Assistant to Senator Daniel Patrick Moynihan. During this period he was also a Visiting Scholar at Brookings Institution, on U.S. Foreign Economic Policy. He was a senior executive at Pfizer, Inc. for 30 years, where he created and then led its International Public Affairs and Public Policy operations and served on Management Boards for a number of its businesses.

Mike is a Member of the Council on Foreign Relations, and from 2010-2013, was Adjunct Senior Fellow with a focus on population aging. In 2013, Mike was invited by then-Committee Chairman Bill Nelson (D-FL) to lead a Members’ Roundtable with the U.S. Senate Special Committee on Aging. Mike was also the recipient of the 2012 Fred D. Thompson Award from the American Federation for Aging Research. He sits on the Boards of the Foreign Policy Association, Business Council for International Understanding, NYC Blood Center, American Skin Association, American Federation for Aging Research and Emigrant Savings Bank, where he is Chairman of its compensation committee. Mike was a member of the World Economic Forum’s Global Agenda Council on Ageing. And he sits on the Advisory Board for the Milken Institute Center for the Future of Aging.

Mike holds a BA, cum laude, Cornell University, M.Sc.in International Relations from The London School of Economics and Political Science, and M.Phil and Ph.D. in Political Science from Columbia University.

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Older Americans Will Suffer If White House Cuts HIV Funding

President Trump’s latest proposal would allow health insurance plans to limit the HIV/AIDs medications they cover through Medicare Part D. Patients relying on Medicare Part D, would be one of six “protected classes” now denied access to their needed medicines. The proposal is shortsighted, as it surely will not save the costs projected in the proposed budget.

How Merrill Lynch Is Planning for Its Customers to Live to 100

The world is getting older. Children born in the developed world today can anticipate living to 100 and beyond, and those of us arriving at old age in good health stand a very good chance of living into our 90s. These shifts will change the workplace environment, and also offer companies new economic opportunities.

The Longevity Economy: Why Seniors Are a Fast-Growing Emerging Market

It’s the mother of all untapped markets: the world’s 65-plus population. Already at a historical high of over 600 million people, it’s projected to hit a full billion by 2030, and 1.6 billion by 2050. And unlike many other fast-growing markets, this expansion will take place primarily in wealthy countries. As